In the claims:

Please amend claims 1, 2, 4-8 and 10 as follows:

1. (Amended) A method for treating or preventing gastritis in a subject, comprising administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP.

2. (Amended) A method for treating or preventing gastric ulceration in a subject, comprising administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin is not a calcitonin or a CGRP.

4. (Amended) [A method of enhancing the analgesic activity of a non-steroidal anti-inflammatory drug in a subject,] The method of claim 1 or 2, further comprising administering [an amylin or an amylin agonist along with said] a non-steroidal anti-inflammatory drug[, wherein said amylin agonist is not a calcitonin].

11 ~~5.~~ (Amended) The method according to any of claims 1-2 [1-4], wherein said subject is human.

12 ~~6.~~ (Amended) The method of according to any of claims 1-2 [1-4], wherein said amylin or amylin agonist is administered by a route selected from the group consisting of nasal, oral, pulmonary, transdermal, and buccal administration.

13 ~~7.~~ (Amended) The method according to any of claims [1-4] 1-2 wherein said amylin agonist is selected from the group consisting of $^{18}Arg^{25,28}Pro$-h-amylin [SEQ. ID. NO. 4],

des-^{1}Lys^{18}Arg^{25,28}Pro-h-amylin [SEQ. ID. NO. 5], ^{18}Arg$^{25-28,29}$Pro-h-amylin [SEQ. ID. NO. 7], des-^{1}Lys^{18}Arg^{25,28,29}Pro-h-amylin [SEQ. ID. NO. 8], $^{25,28-29}$Pro-h-amylin [SEQ. ID. NO. 1], des-^{1}Lys^{25,28,29}Pro-h-amylin [SEQ. ID. NO. 9], ^{25}Pro^{26}Val^{28,29}Pro-h-amylin [SEQ. ID. NO. 6], ^{23}Leu^{25}Pro^{26}Val^{28,29}Pro-h-amylin [SEQ. ID. NO. 10], ^{23}Leu^{25}Pro^{26}Val^{28}Pro-h-amylin [SEQ. ID. NO. 11], des-^{1}Lys^{23}Leu^{25}Pro^{26}Val^{28}Pro-h-amylin [SEQ. ID. NO. 12], ^{18}Arg^{23}Leu^{25}Pro^{26}Val^{28}Pro-h-amylin [SEQ. ID. NO. 13], ^{18}Arg^{23}Leu^{25,28,29}Pro-h-amylin [SEQ. ID. NO. 14], ^{18}Arg^{23}Leu^{25,28}Pro-h-amylin [SEQ. ID. NO. 15], ^{17}Ile^{23}Leu^{25,28,29}Pro-h-amylin [SEQ. ID. NO. 16], ^{17}Ile^{25,28,29}Pro-h-amylin [SEQ. ID. NO. 17], des-^{1}Lys^{17}Ile^{23}Leu^{25,28,29}Pro-h-amylin [SEQ. ID. NO. 18], ^{17}Ile^{18}Arg^{23}Leu-h-amylin [SEQ. ID. NO. 19], ^{17}Ile^{18}Arg^{23}Leu^{26}Val^{29}Pro-h-amylin [SEQ. ID. NO. 20], ^{17}Ile^{18}Arg^{23}Leu^{25}Pro^{26}Val^{28,29}Pro-h-amylin [SEQ. ID. NO. 21], ^{13}Thr^{21}His^{23}Leu^{26}Ala^{28}Leu^{29}Pro^{31}Asp-h-amylin [SEQ. ID. NO. 22], ^{13}Thr^{21}His^{23}Leu^{26}Ala^{29}Pro^{31}Asp-h-amylin [SEQ. ID. NO. 23], des-^{1}Lys^{13}Thr^{21}His^{23}Leu^{26}Ala^{28}Pro^{31}Asp-h-amylin [SEQ. ID. NO. 24], ^{13}Thr^{18}Arg^{21}His^{23}Leu^{26}Ala^{29}Pro^{31}Asp-h-amylin [SEQ. ID. NO. 25], ^{13}Thr^{18}Arg^{21}His^{23}Leu^{28,29}Pro^{31}Asp-h-amylin [SEQ. ID. NO. 26], and ^{13}Thr^{18}Arg^{21}His^{23}Leu^{25}Pro^{26}Ala^{28,29}Pro^{31}Asp-h-amylin [SEQ. ID. NO. 27].

Sub A5

8. (Amended) The method according to any of claims 1-2 [1-4], wherein said amylin agonist is ^{25,28,29}Pro-h-amylin [SEQ. ID. NO. 1].